K. Corbett, D. Edwards, S. Leist, Olubukola M. Abiona, S. Boyoglu-Barnum, Rebecca A. Gillespie, Sunny Himansu, A. Schäfer, Cynthia T. Ziwawo, Anthony T DiPiazza, K. Dinnon, S. Elbashir, C. Shaw, A. Woods, Ethan J. Fritch, D. R. Martinez, Kevin W. Bock, Mahnaz Minai, Bianca M. Nagata, Geoffrey B. Hutchinson, Kai Wu, Carole Henry, K. Bahi, Dario Garcia-Dominguez, Lingzhi Ma, Isabella Renzi, W. Kong, S. Schmidt, L. Wang, Y. Zhang, Emily Phung, Lauren A Chang, R. Loomis, N. Altaras, Elisabeth Narayanan, M. Metkar, V. Presnyak, Cuiping Liu, M. Louder, W. Shi, K. Leung, E. Yang, A. West, K. Gully, Laura J. Stevens, N. Wang, D. Wrapp, N. Doria-Rose, G. Stewart-Jones, H. Bennett, Gabriela Alvarado, M. Nason, T. Ruckwardt, J. McLellan, M. Denison, J. Chappell, Ian N. Moore, Kaitlyn M. Morabito, J. Mascola, R. Baric, A. Carfi, B. Graham
Nature, 2020
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity 1 . This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant 2 SARS-CoV-2 as well as CD8 + T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy. mRNA-1273, an mRNA vaccine that encodes a stabilized prefusion-state severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, elicits robust immune responses and protects mice against replication of SARS-CoV-2 in the upper and lower airways.
Cited by 293 publications.
Field of study: Medicine